Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ: VKTX )

25.74 -0.05 (-0.19%)
Streaming Delayed Price Updated: 11:50 AM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
23 24 Next >
How Viking Therapeutics Stock Could 30x
This mid-cap biopharma may one day be a titan of the industry. 
Via The Motley Fool
Is Viking Therapeutics the Best Biotech Stock for You?
With good mid-stage results and plenty of cash, Viking could be a winner. 
Via The Motley Fool
The 3 Best Russell 2000 Stocks to Buy in May 2024
If you are looking for investments that will deliver high returns, these are the best Russell 2000 stocks to buy for your portfolio. 
Via InvestorPlace
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
The second wave of the weight loss drug stock boom is underway and investors should heed the signs the market is serving. 
Via InvestorPlace
Viking Therapeutics's Options Frenzy: What You Need to Know
Via Benzinga
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy. 
Via InvestorPlace
Here's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years
Via Benzinga
Check Out What Whales Are Doing With VKTX
Via Benzinga
Can This High-Flying Stock 10x in 10 Years?
This midcap biotech could see huge success ahead -- or disappointment. 
Via The Motley Fool
Eli Lilly Gains on the GLP-1 Weight Loss Phenomenon
Eli Lilly stock continues to move higher after the company reported continuing momentum for its flagship GLP-1 weight loss drugs 
Via MarketBeat
Eli Lilly Raised Its Outlook. Is the Stock a Buy Now?
The anti-obesity medication stock is way up, and there could be more fuel in the tank. 
Via The Motley Fool
What Is the Best Weight Loss Stock to Buy Now? Our Top 3 Picks
Data indicates that many more Americans have become aware of the dangers of obesity. Here are the best weight loss stocks to buy now. 
Via InvestorPlace
Stock Market Crash Alert: 3 Must-Buy Biotech Stocks When Prices Plunge
A slip in the market could give investors a rare opportunity to get some top biotech stocks to buy at a considerable discount. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Viking Therapeutics Unusual Options Activity
Via Benzinga
Looking At Viking Therapeutics's Recent Unusual Options Activity
Via Benzinga
Market Whales and Their Recent Bets on VKTX Options
Via Benzinga
Is Viking Therapeutics Incredibly Undervalued?
The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound. 
Via The Motley Fool
1 Little-Known Vanguard Index Fund to Buy Before It Soars 50%, According to a Wall Street Analyst
Tom Lee of Fundstrat Global Advisors thinks the small-cap Russell 2000 could climb 50% by the end of 2024. 
Via The Motley Fool
3 Biotech Stocks to Buy on the Dip: April 2024
With medical innovation being a resilient space, investors can have confidence with these biotech stocks to buy on the dip. 
Via InvestorPlace
3 Millionaire-Maker Biotech Stocks
The risk at these companies is above average, and they're sure to remain volatile. This volatility, however, includes explosively bullish potential. 
Via The Motley Fool
VKTX Stock Earnings: Viking Therapeutics Beats EPS for Q1 2024
VKTX stock results show that Viking Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Viking Therapeutics Reports Q1 Results: 'An Exceptional Period' Says CEO
Viking Therapeutics reports quarterly losses of 26 cents per share which beat the analyst consensus estimate of losses of 28 cents by 7.14%. Research and development expenses were $24.1 million for the... 
Via Benzinga
3 Biotech Stocks With Skyrocketing Potential: April 2024
These three biotech stocks, with robust fundamentals and long-term prospects represent the sector’s finest at this time. 
Via InvestorPlace
3 Red-Hot Biotech Rockets Blasting Off in 2024
The economy is looking very strong and the biotech industry even more so, thus consider these top three stocks for strong profits. 
Via InvestorPlace
Topics Economy
Exposures Economy
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Good news could be just around the corner for two drugmakers not named Novo Nordisk. 
Via The Motley Fool
Better Buy: Pfizer vs. Viking Therapeutics
These two pharma stocks have followed distinct paths of late. Which is the better investment? 
Via The Motley Fool
1 No-Brainer Vanguard Fund to Buy Right Now
This Vanguard growth fund is home to some of the world's most innovative companies. 
Via The Motley Fool
3 Stocks With the Potential to Surpass Analyst Expectations for 2024
These stocks to buy are set to surpass analyst expectations, with exciting product and service developments sparking unforeseen growth. 
Via InvestorPlace
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolio 
Via MarketBeat
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.